Technical Analysis for FBIO - Fortress Biotech, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 18 hours ago |
| Down 2 % | about 18 hours ago |
| Fell Below 10 DMA | about 18 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
| Down 1% | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Fortress Biotech, Inc. Description
Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. It has strategic alliances and commercial agreements with Ovamed GmbHp; Dr. Falk Pharma GmbH; and Freie Universität Berlin. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in Burlington, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Immunotherapy Autoimmune Disease Clinical Development Acute Myeloid Leukemia Cancer Cell Ulcerative Colitis Ulcer Abdominal Pain Colitis Natural Killer Cell Crohn's Disease Eggs Treatment Of Acute Myeloid Leukemia Treatment Of Autoimmune Disease Autism Spectrum Disorder Autism
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.43 |
| 52 Week Low | 1.2494 |
| Average Volume | 591,665 |
| 200-Day Moving Average | 1.87 |
| 50-Day Moving Average | 1.77 |
| 20-Day Moving Average | 1.77 |
| 10-Day Moving Average | 1.87 |
| Average True Range | 0.11 |
| RSI (14) | 57.81 |
| ADX | 25.62 |
| +DI | 27.23 |
| -DI | 13.96 |
| Chandelier Exit (Long, 3 ATRs) | 1.76 |
| Chandelier Exit (Short, 3 ATRs) | 1.84 |
| Upper Bollinger Bands | 2.05 |
| Lower Bollinger Band | 1.49 |
| Percent B (%b) | 0.73 |
| BandWidth | 31.75 |
| MACD Line | 0.07 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.0226 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.04 | ||||
| Resistance 3 (R3) | 2.05 | 2.00 | 2.02 | ||
| Resistance 2 (R2) | 2.00 | 1.96 | 2.00 | 2.01 | |
| Resistance 1 (R1) | 1.95 | 1.94 | 1.93 | 1.95 | 2.00 |
| Pivot Point | 1.91 | 1.91 | 1.89 | 1.90 | 1.91 |
| Support 1 (S1) | 1.86 | 1.87 | 1.83 | 1.85 | 1.80 |
| Support 2 (S2) | 1.81 | 1.85 | 1.81 | 1.79 | |
| Support 3 (S3) | 1.76 | 1.81 | 1.78 | ||
| Support 4 (S4) | 1.76 |
